in this method we use a linear equation to resolve two-component decay data from the urea inactivation of mixtures of alkaline phosphatase (EC 3.1.3.1) of liver and bone origin. The specificity for the bone/liver isoenzyme is enhanced by including L-phenylalanine in the urea reaction to inhibit the intestinal and placental forms. Bone and liver fractions are each quantified from results of a single run on the centrifugal analyzer. Total activity and the L-phenylalanine-inhibited fraction are measured on separate runs. A simplification of this method has been used in our laboratory for 14 years in performing >80 000 analyses of clinical specimens. Speed, accuracy, and precision are improved over previous methods by this mathematical solution. Data reduction is automated through the use of a personal computer interfaced to the analyzer. With such systems generally available, this method can now be suggested as suitable for routine use to separate these and perhaps other isoenzyme mixtures.
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The isoenzymes of alkaline phosphatase (ALP, EC 3.1.3.1) are recognized as products of at least three structural gene loci. These are responsible for the bone! liver/kidney, intestinal, and placental forms (1) . Any tissue specificity observed for the bone and liver types is a result of post-translational changes to otherwise identical proteins. The difficulties associated with separating and quantifring each type from a mixture is well known (2) . However, reproducible inactivation by heat (3) (4) (5) or chemicals (3, (6) (7) (8) (9) (10) (11) (12) (13) (14) can be used to differentiate these forms. Statland et al. (8) reported a method in which both L-phenylalanine and urea inhibition were used in centrifugal analysis to measure ALP isoenzymes. An approximation of the contribution of each fraction was calculated from an assumption that the differential inhibition is constant. To maintain accuracy and precision in this end-point determination with differential inhibition, one would need to strictly control timing and other variables. In practice, this is difficult; however, a more thorough examination of the data reveals a solution through resolution of the combined decay curve of the liver and bone mixture (15) . The initial noncompetitive inhibition of activity by urea is followed by a time-dependent inactivation similar to that of heat inactivation (4, 6) . This yields an analysis that is independent of the major variables because results are determined from least-squares linear regression of all the data points, with tissue-specific standards included in each run. The proportion of each component can be quantified reliably over a broad range of total activity and isoenzyme distribution.
Materials and Methods
Reagents
The assays are all performed in diethanolamine buffer with p-nitrophenyl phosphate as a substrate, with only minor departures from the method of Statland et al. (8) 
Standards
Four standards are prepared and diluted to -300 UIL with cold bovine albumin solution (50 gIL); 0.5-mL aliquots are then prepared and stored frozen at -70 #{176}C.
Bone standard (B). Sera from patients with osteoblastic bone disease (Paget's) and greatly increased ALP can be tested for use in a pooled bone standard. Specimens selected for pooling should demonstrate a high rate of urea inactivation.
Liver standard (L) . Similarly, sera from patients diagnosed as having hepatobiliary disease can be tested for use as a pooled reference standard. Selection of only those sera having a uniformly low rate of inactivation ensures an insignificant contribution of bone isoenzyme. Attempts to use tissue homogenates, with or without n-butanol extraction, to create liver standards have not proven successful. The rates of inactivation in these preparations do not correspond to those found in patients' sera (5) . The enzyme released in vivo is clearly different, resulting in a lower rate of urea inactivation. Alternatively, the intestinefree standard can be obtained by using serum from someone with type A blood, whose total ALP activity exceeds 250 U/L. Populations with type A blood have the lowest intestinal ALP activities (10) . This standard should show -18% inhibition after treatment with phenylalanine.
Control materials.
Two control materials can be prepared by pooling sera having a mixture of bone and liver fractions. Using cold bovine albumin solution (50 gIL), adjust the controls to have normal and abnormal concentrations of ALP activity. The above-normal control should also contain enough concentrated mucosa preparation that 15-25 U of intestinal ALP per liter will be present.
Procedures
The analysis consists of three separate runs: total activity, phenylalanine inhibition, and urea inactivation.
Total and phenylalanine inhibition.
Sample trays for the total activity and phenylalamne-inhibited activity are loaded with standard "A" in duplicate, followed by standard "I" in duplicate, followed by the normal and abnormal controls. The data from each run are entered into the computer and used to calculate the phenylala- The proportion of phenylalanmne-mnhibitable activity present in the unknown specimen is calculated by linear interpolation as follows:
An alternative method (10), in which L-p-bromotetramisole inhibits the bone/liver fraction, might be used in a similar fashion. The fraction so calculated would represent any contribution by intestinal, placental, Began, and certain other neoplastic forms of ALP.
Urea inactivation. Standards"A" and "I" are replaced with standards "B" and "L," respectively, for the urea inactivation analysis.
Both heat and urea inactivation are time-dependent, irreversible, first-order reactions that resemble radionucleotide decay, described as follows (5, 6, 15) :
where: A = activity change in absorbance (A) per minute A#{176} = activity at time zero A = rate of inactivation = (A/min)/min
The rates of inactivation of bone-and liver-type ALP are unique for a given analytical run. This rate of inactivation (A) is calculated as the slope of a leastsquares linear regression, plotting ln(.A) vs time (Figure 1) . The means of the results for the duplicate bone and liver standards are obtained (A1 and A2, respectively). The inactivation of a mixture of these forms in the unknown specimen is then represented by the following equation:
A A?e' + Ae_A2t which represents the sum of activities remaining in a mixture when the two components inactivate according to first-order kinetics at time t with individual decay constants -A (15) .
A simple solution to the determination of the relative contributions of each species would be to plot the natural logarithm of activity vs time until the more quickly disappearing fraction has been depleted. Again, the study of heat inactivation has borne this out (4) . A least-squares linear regression of the remaining inactivation curve is subtracted from the total to determine the proportion of each. However, this approach has some inherent imprecision associated with assessing the linear portion of the curve, particularly if the liver contribution is small.
Another solution, for A1> A2,would be to multiply the previous equation by e2t to give 0, 100%liver; #{149}, 80% liver; 0, 60% liver; , 40%liver; , 20% liver;A, 100% bone = oo) to 1 (t = 0). A least-squares linear regression fit of the observed data from the patients' specimens can be used to determine the proportion of bone and liver present: When x = 0, the y-intercept represents the starting activity of the liver isoenzyme; when x = 1, the y-intercept is the total activity (16) . The initial bone activity can be calculated by subtraction, which is also equivalentto the slope (Figure 2 ). Species that might have inactivation constants greater than bone or less than liver would not contribute to the linear portion of the curve (17) . The correlation coefficient of the regression analysis can be used as a further validation of the presence of only two unique rates of inactivation and as a QC indicator for specimens that have exceeded the limits of sensitivity. Discrimination of species by this method is best if A1is at least fourfold A2 (15) . Fortunately, for bone and liver isoenzymes, the ratio is about 4. The inactivation depends on urea concentration, pH, and temperature. These variables should be controlled; but, as long as standards are included in each analytical run, the results will be consistent over a broad range of activities and isoenzyme proportion (Figure 3) .
The results of this calculation might best be labeled 000 400 600 800 000
IJ/L,Simplified Calculation "liver type" and "bone type," inasmuch as tumors and other organs may certainly produce isoenzymes that are similarly inactivated by urea (9, 18, 20 and some tumor isoenzymes are blocked by the presence of L-phenylalanine, which inhibits 85% of this activity. The activities of liver and bone forms are both inhibited 18% by phenylalanine, so their relative proportions remain constant. The urea analysis is always accompanied by quantification of phenylalanine-inhibitable type to produce a more complete isoenzyine profile. It would also be appropriate to have available an electrophoretic procedure when confirmation of intestinal and placental forms is necessary (these forms are easily distinguished by electrophoresis).
Results and Discussion
The differential inactivation of urea to discriminate bone-and liver-type ALP has been used by our laboratory for 14 years to analyze >80 000 patients' specimens by linear interpolation between bone and liver standards, with use of rates of inactivation (A) for the standards and unknown (unpublished). However, this approximation necessitates conditions that produce low rates of inactivation, such that the proportion of bone and liver ALP does not change significantly during the course of the reaction. The usefulness of that assay is, therefore, limited to only those specimens that have above-normal total ALP and a large change in absorbance. The new mathematical approach we report correlates with the previous method and with an HPLC method (19) (Figure 4) , and has the advantage of resolution at normal concentrations of total activity.
The difficulty in implementing this approach for routine isoenzyme analysis is associated with data reduction. The authors of the original concept, as applied to radionucleotide decay, alluded to the tedious nature of the calculations and the need for "an electronic digital computer" (15, 17) . Over the years, we have modified hardware and software (and even fabricated a microcomputer) to capture data and calculate results for this analysis as performed with various centrifugal analyzers, including the EM Gemsaec, the Union Carbide! Baker CentrifiChem (300-500 series), the Baker Encore, and the Instrumentation Laboratory Monarch. Laboratories now have a plethora of computers as well as instrument interfacing at their disposal. With the advent of the "personal computer" and more flexible alternatives for data output from analytical instruments, we suggest that this calculation can now be used routinely by laboratories for resolution of alkaline phosphatase and, perhaps, other isoenzymes.
